Prostate tumours are highly variable in their response to therapies, but clinically available
prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 …

The cancer transcriptome is remarkably complex, including low-abundance transcripts, many
not polyadenylated. To fully characterize the transcriptome of localized prostate cancer, we …

The Hippo pathway is a key growth control pathway that is conserved across species. The
downstream effectors of the Hippo pathway, YAP (Yes-associated protein) and TAZ (…

The prostate cancer (PCa) risk-associated SNP rs11672691 is positively associated with
aggressive disease at diagnosis. We showed that rs11672691 maps to the promoter of a short …

The acquisition of cancer hallmarks requires molecular alterations at multiple levels including
genome, epigenome, transcriptome, proteome, and metabolome. In the past decade, …

Long noncoding RNAs (lncRNAs) represent an attractive class of candidates to mediate
cancer risk. Through integrative analysis of the lncRNA transcriptome with genomic data and …

Cancers adapt to increasingly potent targeted therapies by reprogramming their phenotype.
Here we investigated such a phenomenon in prostate cancer, in which tumours can escape …

Neuroendocrine prostate cancer (NEPC), a lethal form of the disease, is characterized by
loss of androgen receptor (AR) signaling during neuroendocrine transdifferentiation, which …

FOXA1 functions as a pioneer transcription factor by facilitating the access to chromatin for
steroid hormone receptors, such as androgen receptor and estrogen receptor 1 , 2 , 3 – 4 , but …

Lysine-Specific Demethylase 1 (LSD1, KDM1A) functions as a transcriptional corepressor
through demethylation of histone 3 lysine 4 (H3K4) but has a coactivator function on some …